ArticleDiscover oncology2025
The choice of adjuvant radiotherapy in adrenocortical carcinoma patients after radical adrenalectomy: a population-based analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to more accurately screen the adrenocortical carcinoma(ACC) patients who would benefit from adjuvant radiotherapy after radical adrenalectomy.
methodsThe clinicopathological data from 2000 to 2018 were downloaded from the SEER database. All patients were divided into two groups: surgery alone and surgery followed by radiotherapy. A propensity score-matched(PSM) pair analysis was performed to reduce potential selection bias. The Chi-square test examined differences between groups. Univariate and multivariate analyses were applied to identify prognostic factors affecting patient survival. Kaplan-Meier analysis estimated the two groups' overall survival (OS).
results636 ACC patients who underwent radical adrenalectomy were enrolled. Among them, 95 patients (14.94%) had undergone adjuvant radiotherapy, whereas 541 (85.06%) received surgery only. After PSM, 89 received adjuvant radiotherapy, and 89 received surgery alone. Before PSM, the patients did not benefit from adjuvant radiotherapy, while the OS of the adjuvant radiotherapy group was better than that of surgery alone after PSM(P = 0.028). Univariate Cox regression analysis showed that radiotherapy, sex, tumor size, disease stage, grade, and lymph node status were correlated with OS. Multivariable Cox regression analysis demonstrated that age, disease stage, lymph node status, and adjuvant radiotherapy influenced overall survival. Patients were risk-stratified based on known high-risk features for relapse or death; the adjuvant radiotherapy was significantly associated with more prolonged survival(P = 0.031) in the high-risk group but not the low-risk group.
conclusionOur study shows that ACC patients after radical adrenalectomy could benefit from adjuvant radiotherapy, especially in high-risk patients. So, we can take ACC patients after radical adrenalectomy and with more high-risk features(risk factor ≥ 2) as a potential beneficiary of adjuvant radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.